Re, 3rd. L. , V, Haynes, K. ., Ming, E. E., Ives, W. ., Horne, L. N., Fortier, K. ., … Strom, B. L. (2012). Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3318
D. Esposito
First name
D.
Middle name
B.
Last name
Esposito
Saine, M. E., Carbonari, D. M., Newcomb, C. W., Nezamzadeh, M. S., Haynes, K. ., Roy, J. A., … Re, V. 3rd L. (2015). Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacol Toxicol. http://doi.org/10.1186/s40360-015-0007-z
Saine, M. E., Gizaw, M. ., Carbonari, D. M., Newcomb, C. W., Roy, J. A., Cardillo, S. ., … Re, V. 3rd L. (2017). Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4368
Re, L. ., Carbonari, D. M., Saine, M. E., Newcomb, C. W., Roy, J. A., Liu, Q. ., … Strom, B. L. (2017). Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000400